Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Travere Therapeutics, Inc.NASDAQ: TVTX

Income Before Tax · Q3 FY2026 · quarter ended Sep 2026

Income before tax turns negative

Q3 FY2026 income before tax was -$66.93M, compared with $25.71M a year earlier. Trailing-twelve-month income before tax was -$159.72M.

Context

  • Income before tax amounted to 10.0% of revenue in FY2025, down 127.4 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$66.93M or moves back toward the trailing-twelve-month quarterly average of -$39.93M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$66.93M-91.2% QoQ
Last fiscal yearDec 2025
-$49.27M+84.6% YoY
LTMSep 2026
-$159.72M-80.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-360.3%——
1 year+84.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(49.27M) USD
Year-over-year change
+84.6%

Income Before Tax vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 income before tax of -$159.72M is the 4th highest of the 5 companies compared; the peer median is -$139.5M.
  • Its year-over-year change of -80.4% is the 3rd highest of 5, against a peer median of -38.7%.
  • Income before tax amounts to 24.5% of revenue for TVTX, versus a peer median of 612.7%.
TVTX Competitors Peer median
Income Before Tax for TVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PHARPharming Group N.V.LTM Mar 2026$19.88M +643.8%-4.9%5.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$122.54M -330.7%—612.7%
PROKProKidney Corp.LTM Mar 2026-$156.46M +5.8%—17599.3%
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$159.72M -80.4%—24.5%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$349.58M -83.2%——
Peer median (excluding TVTX) -$139.5M-38.7%-4.9%612.7%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue131.84M109.46M145.24M233.18M490.73M
Cost of Revenue3.82M4.42M11.45M7.74M10.34M
Gross Profit128.02M105.04M133.79M225.43M480.39M
Gross Margin97.1%96.0%92.1%96.7%97.9%
Research & Development201.16M227.33M244.99M282.7M206.01M
Selling, General & Admin126.28M197.52M265.54M264.12M337.2M
Operating Expenses327.44M424.85M521.93M549.26M543.21M
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
EBITDA(184.46M)(299.42M)(326.25M)(265.77M)22.22M
EBITDA Margin-139.9%-273.5%-224.6%-114.0%4.5%
Operating Income(199.43M)(319.81M)(388.14M)(323.83M)(62.82M)
Operating Margin-151.3%-292.2%-267.2%-138.9%-12.8%
Interest Income1.99M6.28M21.77M17.82M12.72M
Interest Expense19.68M11.01M11.33M11.18M10.75M
Other Income / Expenses(17.46M)(11.34M)12.03M3.32M13.55M
Income Before Tax(216.88M)(331.16M)(376.11M)(320.51M)(49.27M)
Pre-Tax Margin-164.5%-302.5%-259.0%-137.5%-10.0%
Income Tax Expense409K313K223K120K988K
Net Income(180.09M)(278.48M)(111.4M)(321.55M)(25.55M)
Net Margin-136.6%-254.4%-76.7%-137.9%-5.2%
EPS (Basic)(3.01)(4.37)(1.50)(4.08)(0.56)
EPS (Diluted)(3.01)(4.37)(1.50)(4.08)(0.56)
Weighted Avg Shares59.83M63.76M74.27M78.89M89.21M
Weighted Avg Shares (Diluted)59.83M63.76M74.27M78.89M89.21M

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.